122 related articles for article (PubMed ID: 18058576)
1. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
Newman S
Curr Opin Investig Drugs; 2007 Dec; 8(12):1057-66. PubMed ID: 18058576
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
Polastro L; Aftimos PG; Awada A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
[TBL] [Abstract][Full Text] [Related]
3. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
Mani S; Swami U
Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
[TBL] [Abstract][Full Text] [Related]
4. Eribulin: rediscovering tubulin as an anticancer target.
Jimeno A
Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
[TBL] [Abstract][Full Text] [Related]
5. Advances in therapy: eribulin improves survival for metastatic breast cancer.
Morris PG
Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
9. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
10. Complex synthesis yields breast-cancer therapy.
Ledford H
Nature; 2010 Dec; 468(7324):608-9. PubMed ID: 21124423
[No Abstract] [Full Text] [Related]
11. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.
Alday PH; Correia JJ
Biochemistry; 2009 Aug; 48(33):7927-38. PubMed ID: 19586046
[TBL] [Abstract][Full Text] [Related]
12. Eribulin in Cancer Treatment.
Swami U; Shah U; Goel S
Mar Drugs; 2015 Aug; 13(8):5016-58. PubMed ID: 26262627
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
Renouf DJ; Tang PA; Major P; Krzyzanowska MK; Dhesy-Thind B; Goffin JR; Hedley D; Wang L; Doyle L; Moore MJ
Invest New Drugs; 2012 Jun; 30(3):1203-7. PubMed ID: 21526355
[TBL] [Abstract][Full Text] [Related]
14. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
Seetharam M; Kolla KR; Chawla SP
Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
Towle MJ; Salvato KA; Budrow J; Wels BF; Kuznetsov G; Aalfs KK; Welsh S; Zheng W; Seletsky BM; Palme MH; Habgood GJ; Singer LA; Dipietro LV; Wang Y; Chen JJ; Quincy DA; Davis A; Yoshimatsu K; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2001 Feb; 61(3):1013-21. PubMed ID: 11221827
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S; Italiano A
Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
18. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
19. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
20. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
